Electrochemical molecularly bioimprinted siloxane biosensor on the basis of core/shell silver nanoparticles/EGFR exon 21 L858R point mutant gene/siloxane film for ultra-sensing of Gemcitabine as a lung cancer chemotherapy medication

In search for improvements in bioanalysis electrochemical sensors, for better assessment of anti-cancer drugs, it is necessary for their detection limits to be minimized and the sensitivity and selectivity to be surpassed simultaneously; whereas, resolving any probable interfering with other medical treatments are considered. In this work, a novel approach was adopted for detection and assessment of Gemcitabine (GEM) as an anti-cancer drug based on evaluating its interaction with EGFR exon 21-point mutant gene. An electrochemical nanobiosensor was invented based on a new molecularly bioimprinted siloxane polymer (MBIS) strategy; in which the EGFR exon 21 acts as an identification probe. The roles of multi-walled carbon nanotubes and Ag nanoparticles (NPs) are to perform as a signal amplifier. The MBIS film was prepared by acid-catalysed hydrolysis/condensation of the sample solution, containing Ag NPs, ds-DNA of EGFR exon 21 point mutant gene, GEM as a template molecule, 3-(aminopropyl) trimethoxysilane (APTMS) and tetraethoxysilane. The interaction between the dsDNA and GEM was investigated by employing the modified biosensor and monitoring oxidation signal of guanine and adenine. The produced biosensor was characterized by XRD, FE-SEM, EDS, FT-IR and differential pulse voltammetry. The oxidation signals of adenine and guanine were in linear range when the device was subjected to various concentrations of GEM, from 1.5 to -93 mu M, where a low detection limit 12.5 nmol L-1, and 48.8 nmol L-1 were recorded by guanine and adenine respectively. The developed biosensor did perform very well when employed for the actual samples; the stability was also approved which was acceptable for a reasonable time.